Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

NCT04642937 Phase 1 UNKNOWN

This is a single-center, open-label, dose-range finding Phase I study of hP1A8, a new adjuvant CD200 activation receptor ligand (CD200AR-L), in combination with imiquimod and the GBM6-AD vaccine to treat recurrent glioblastoma (GBM) in adults.

Details

Lead sponsor	OX2 Therapeutics
Phase	Phase 1
Status	UNKNOWN
Enrolment	24
Start date	2020-12-01
Completion	2024-11

Conditions

• Glioblastoma

Interventions

• Treatment with hP1A8

Primary outcomes

• Maximum tolerated dose (MTD) of hP1A8 when administered with imiquimod and GBM6-AD — 12 months

Countries

United States